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Certain protein toxins act by catalytically modifying
substrates in the cytosol of mammalian cells. To reach
this compartment, these proteins undergo retrograde
transport from the cell surface, via the Golgi complex,
to the endoplasmic reticulum.
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The secretory pathway transports correctly folded proteins
from the endoplasmic reticulum (ER) to the plasma mem-
brane, culminating in their discharge from the cell. Trans-
port proceeds via the Golgi stack and is mediated by
vesicular carriers that bud from one compartment on the
pathway and fuse with the next. It has been known for
some time that this anterograde protein transport is at least
partially reversible. Certain resident proteins present in the
ER lumen and membrane can escape this compartment
and reach the Golgi complex, where they acquire Golgi-
specific modifications to oligosaccharide side chains, before
being returned to the ER by virtue of retrieval signals, such
as the carboxy-terminal tetrapeptides KDEL (single-letter
amino-acid code) or KKXX [1]. In the case of retrieval
mediated by the KDEL receptor, this can occur from all
Golgi cisternae including the trans-Golgi network (TGN). 
The TGN type I transmembrane protein TGN38
contains targeting signals that allow it to recycle, albeit at a
low level, between the TGN, where most of the protein is
located, and the plasma membrane. A synthetic peptide
with a carboxy-terminal KDEL retrieval signal, which was
disulphide linked to an antibody recognising a tagged
version of TGN38, accumulated in the TGN and, after
reductive release from the antibody, underwent retrograde
transport to the ER lumen [2]. This clever experiment
showed that transport from the cell surface to the ER was
possible, but is this complete reverse of anterograde trans-
port of any physiological significance? Recent studies into
the fate of certain protein toxins that enter mammalian
cells by endocytosis have shown that the answer to this
question is yes.
Some plants and bacteria produce proteins that are
potently toxic to mammalian cells. These toxins act by
catalytically modifying target substrates so that essential
cellular processes, protein synthesis for example, are
blocked. The toxins are members of the so-called AB-
toxin family, in which the catalytically active polypeptide
or fragment (A) is associated with one or more cell-binding
(B) components. These toxins bind to receptors on the
surface of susceptible cells and enter by endocytosis in a
clathrin-mediated or clathrin-independent manner,
depending on the type of receptor being internalised
(Figure 1). As the target substrates are in the cytosol, the
A polypeptides must traverse an intracellular membrane
in order to reach them. 
The issues of where and how the toxin A polypeptides are
translocated across an intracellular membrane into the
cytosol are being increasingly studied. All endocytosed
Figure 1
Retrograde transport of endocytosed toxins. Toxins such as ricin,
Shiga toxin and exotoxin A bind surface components and enter cells by
clathrin-mediated or clathrin-independent endocytosis to reach the
endosomal system. Most of the toxin in endosomes is either recycled
back to the surface or transported to lysosomes for degradation. A
small proportion of the endocytosed toxin is transported to the TGN —
the productive route for subsequent intoxication. The toxin undergoes
retrograde vesicular transport from the TGN, via the Golgi cisternae, to
the ER before the catalytic A fragment crosses a membrane. This
pathway may be very inefficient, but the extreme potency of these
toxins ensures that a lethal amount enters the cytosol.
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toxins are initially delivered to endosomes, and they can be
divided into two groups: those that translocate from acidi-
fied endosomes and those that do not. The most promi-
nent member of the former group is diphtheria toxin, and
other members include anthrax, botulinum and tetanus
toxins. The low pH in endosomes induces a conforma-
tional change in diphtheria toxin that triggers translocation
of the diphtheria toxin A fragment into the cytosol by a
mechanism described in more detail elsewhere [3]. 
Toxins that do not translocate from acidified endosomes
include Pseudomonas aeruginosa exotoxin A, Shiga toxin,
the Shiga-like toxins, cholera toxin and heat-labile entero-
toxin from bacteria, and ricin and abrin from plants. These
toxins must be transported beyond endosomes before the
translocation site is reached. Electron microscopic moni-
toring of endocytosed ricin showed that some toxin
reached the TGN [4]. Transport from the TGN to, or
through, the Golgi stack seemed to be essential for cyto-
toxicity, however, as disrupting the Golgi stack by
brefeldin A treatment protected cells from intoxication
but did not prevent toxin from reaching the TGN [5,6]. In
MDCK cells, brefeldin A treatment did not disrupt the
Golgi stack and the cells remained sensitive to toxin [6]. 
A key observation made with exotoxin A suggested that
the ER could be the site of toxin translocation, and pro-
vided a likely explanation of how retrograde transport
from the TGN to this compartment could be achieved.
The last five residues at the carboxyl terminus of the exo-
toxin A fragment that translocates to the cytosol are
REDLK. The terminal K residue could be deleted
without effect, but further deletions or substitutions, pre-
dicted to prevent interaction with the KDEL receptor,
dramatically reduced cytotoxicity [7]. It was also noted
that the carboxy-terminal four residues of the catalytic
polypeptide of cholera toxin are KDEL, and those of heat-
labile enterotoxin are RDEL. The cytotoxic activity of
these G-protein-modifying toxins is not absolutely depen-
dent on the KDEL/RDEL tetrapeptide, although it does
appear to enhance delivery into the cytosol [8]. These
observations strongly suggest, without directly proving,
that these toxins require retrograde transport to the ER
before they enter the cytosol.
Do proteins such as ricin or Shiga toxin, which do not have
a KDEL or related retrieval signal, also reach the ER
lumen before translocating into the cytosol? This was sug-
gested to be the case [9], a conclusion strengthened for
endocytosed Shiga toxin by its visualisation in the ER [10].
Recently, biochemical evidence that both ricin and Shiga
toxin are transported to the ER via the Golgi has been pre-
sented. In the case of ricin, the A polypeptide was modified
at the carboxyl terminus by the inclusion of a sulphation
site and overlapping N-glycosylation sites [11]. These mod-
ifications to a recombinant, non-glycosylated ricin A chain
did not prevent its reassociation with ricin B, and ricin con-
taining the modified A chain had the same cytotoxicity as
native ricin, suggesting that the modifications were not
affecting the intoxication process in any way. When this
ricin was incubated with cells in the presence of Na2 35SO4,
the A chains became labelled. Because sulphation occurs in
the TGN, only that proportion of the endocytosed toxin
that had reached this organelle was labelled. 
Rapak et al. [11] found that only a small proportion of the
endocytosed ricin reaches the TGN — the bulk of the
toxin that enters endosomes is either recycled back to the
cell surface or transported to lysosomes where it is pre-
sumably degraded. The 35S-labelled A chain therefore
represented only a minor part of the intracellular ricin
population but, crucially, it is the part that is on the pro-
ductive pathway for intoxication. This portion of the 35S-
labelled A chain also became N-glycosylated, showing that
it had undergone retrograde transport from the Golgi to
the ER lumen. Subsequently, glycosylated A chain was
recovered from the cytosolic fraction. Although the cells
contained both unglycosylated and glycosylated 35S-
labelled A chain, only the glycosylated form was found in
the cytosol. This clearly showed that translocation into the
cytosol occurred only after the toxin had been transported
to the ER lumen.
A similar experimental approach using Shiga toxin led to
the same conclusions [12]. In this case, a recombinant B
polypeptide was constructed carrying an N-glycosylation
site and a carboxy-terminal KDEL retrieval signal. Once
again this molecule, when presented to cells, became N-
glycosylated. Morphological studies showed that the
protein was transported from the plasma membrane, via
endosomes and the Golgi cisternae, to the ER. The intro-
duction of a sulphation site into the protein further con-
firmed that it entered the Golgi complex via the TGN. A
version of the B polypeptide containing a non-functional
ER retrieval sequence (KDELGL) also became N-glyco-
sylated — at the same rate as the B polypeptide with the
functional retrieval sequence — but localised at steady
state to the Golgi rather than the ER. This implied that
the Shiga toxin B chain is not dependent on a direct
interaction with the KDEL receptor for retrograde
transport from the TGN to the ER. It is possible that the
glycosphingolipid Shiga toxin receptors themselves are
able to carry the Shiga toxin ligand from the cell surface
to the ER.
Although it seems clear that several protein toxins can
undergo retrograde transport from the cell surface to the
ER, and that transport via the Golgi is required for cytotoxi-
city, the site and mechanism of A-chain translocation
remain to be established. It is tempting to speculate that
translocation into the cytosol takes place in the ER
(Figure 2). As noted above, the toxins represent two distinct
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groups. The first includes those, exemplified by diphthe-
ria toxin, capable of responding to the environment within
endosomes to make, or contribute to the formation of, a
protein-conducting pore through which their A fragments
can pass. Members of the second group lack this ability
and must, therefore, reach a compartment where protein-
conducting channels already exist — the ER. 
If the ER is indeed the site of translocation, and at present
this is purely conjecture, it seems likely that the routing of
toxin to the ER permits the exploitation of a pre-existing
protein-export machinery. An obvious candidate for this
role is the ER-associated protein degradation pathway
[13]. This pathway disposes of misfolded or unassembled
proteins in the ER lumen by exporting them, via the
Sec61p translocon [14,15], for degradation by the cytosolic
ubiquitin/proteasome pathway. Toxin A fragments may be
perceived as misfolded or unassembled proteins, resulting
in their transfer to the cytosol by ER-associated protein
degradation. If this proves to be the case, the toxins must
have a further trick in their repertoire — a mechanism to
avoid rapid degradation by the proteasome system. 
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Figure 2
Hypothetical site and mechanism of toxin translocation. Upon reaching
the ER lumen, the catalytic A fragment is reductively released from the
cell binding B fragment(s). This step may be mediated by protein
disulphide isomerase (PDI) and is known to occur even in the oxidising
environment of the ER lumen [16,17]. The A fragment may be
perceived by the ER-associated protein degradation pathway as
unassembled or may partially unfold resulting in its export, possibly
through the Sec61p translocon, and proteolysis in the cytosol.
Hydrophobic stretches in the A fragment, exposed after release from
the B fragment(s), may facilitate membrane insertion. Some or all of the
exported toxin must avoid ubiquitination/proteasomal degradation,
assume its active conformation, and modify the cytosolic substrate.
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